G. Ottaviani and N. Jaffe, The Epidemiology of Osteosarcoma, Cancer Treat Res, vol.152, pp.3-13, 2009.
DOI : 10.1007/978-1-4419-0284-9_1

M. Klein and G. Siegal, Osteosarcoma, American Journal of Clinical Pathology, vol.125, issue.4, pp.555-581, 2006.

S. Botter, D. Neri, and B. Fuchs, Recent advances in osteosarcoma, Current Opinion in Pharmacology, vol.16, pp.15-23, 2014.
DOI : 10.1016/j.coph.2014.02.002

C. Gibbs, P. Levings, and S. Ghivizzani, Evidence for the osteosarcoma stem cell, Current Orthopaedic Practice, vol.22, issue.4, pp.322-326, 2011.
DOI : 10.1097/BCO.0b013e318221aee8

S. Bielack, B. Kempf-bielack, G. Delling, G. Exner, S. Flege et al., Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols, Journal of Clinical Oncology, vol.20, issue.3, pp.776-790, 2002.
DOI : 10.1200/JCO.2002.20.3.776

A. Davis, R. Bell, and P. Goodwin, Prognostic factors in osteosarcoma: a critical review., Journal of Clinical Oncology, vol.12, issue.2, pp.423-431, 1994.
DOI : 10.1200/JCO.1994.12.2.423

J. Friebele, J. Peck, X. Pan, M. Mayerson, and J. , Osteosarcoma: a meta-analysis and review of the literature, Am J OrthopBelle Mead NJ), vol.44, pp.547-553, 2015.

A. Luetke, P. Meyers, I. Lewis, and H. Juergens, Osteosarcoma treatment ??? Where do we stand? A state of the art review, Cancer Treatment Reviews, vol.40, issue.4, pp.523-532, 2014.
DOI : 10.1016/j.ctrv.2013.11.006

G. Rosen, R. Marcove, B. Caparros, A. Nirenberg, C. Kosloff et al., Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery, Cancer, vol.36, issue.6, pp.2163-2177, 1979.
DOI : 10.1007/978-3-642-95227-2_24

O. Kane, G. Cadoo, K. Walsh, E. Emerson, R. Dervan et al., Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review, Clin Sarcoma Res, vol.5, p.17, 2015.

P. Picci, G. Bacci, M. Campanacci, M. Gasparini, S. Pilotti et al., Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor, Cancer, vol.153, issue.7, pp.1515-1521, 1985.
DOI : 10.1148/radiology.149.3.6580673

D. Hanahan and L. Coussens, Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment, Cancer Cell, vol.21, issue.3, pp.309-322, 2012.
DOI : 10.1016/j.ccr.2012.02.022

A. Alfranca, L. Martinez-cruzado, J. Tornin, A. Abarrategi, T. Amaral et al., Bone microenvironment signals in osteosarcoma development, Cellular and Molecular Life Sciences, vol.128, issue.2, pp.3097-3113, 2015.
DOI : 10.1002/ijc.25331

M. Junttila and F. De-sauvage, Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, vol.37, issue.7467, pp.346-354, 2013.
DOI : 10.1038/ng1596

P. Farmer, H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati et al., A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer, Nature Medicine, vol.57, issue.1, pp.68-74, 2009.
DOI : 10.1186/bcr1608

M. Meads, L. Hazlehurst, and W. Dalton, The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance, Clinical Cancer Research, vol.14, issue.9, pp.2519-2526, 2008.
DOI : 10.1158/1078-0432.CCR-07-2223

L. Yu, W. Guo, S. Zhao, F. Wang, and Y. Xu, Fusion between cancer cells and myofibroblasts is involved in osteosarcoma, Oncology Letters, vol.2, issue.6, pp.1083-1087, 2011.
DOI : 10.3892/ol.2011.363

I. Ader, C. Gstalder, P. Bouquerel, M. Golzio, G. Andrieu et al., Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer, Oncotarget, vol.6, issue.15, pp.13803-13821, 2015.
DOI : 10.18632/oncotarget.3144

S. Mckeown, Defining normoxia, physoxia and hypoxia in tumours???implications for treatment response, The British Journal of Radiology, vol.61, issue.1035, p.20130676, 2014.
DOI : 10.1186/1471-2407-12-496

O. Trédan, C. Galmarini, K. Patel, and I. Tannock, Drug Resistance and the Solid Tumor Microenvironment, JNCI Journal of the National Cancer Institute, vol.99, issue.19, pp.1441-1454, 2007.
DOI : 10.1093/jnci/djm135

M. Joliat, S. Umeda, B. Lyons, M. Lynes, and L. Shultz, Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma, In Vivo, vol.16, pp.223-228, 2002.

M. Tomayko and C. Reynolds, Determination of subcutaneous tumor size in athymic (nude) mice, Cancer Chemotherapy and Pharmacology, vol.45, issue.3, pp.148-154, 1989.
DOI : 10.1038/bjc.1985.57

V. Tuominen, S. Ruotoistenmäki, A. Viitanen, M. Jumppanen, and J. Isola, ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67, Breast Cancer Research, vol.8, issue.4, p.56, 2010.
DOI : 10.1038/nm791

S. Hartig, Basic Image Analysis and Manipulation in ImageJ, Curr Protoc Mol Biol, vol.4, 2013.
DOI : 10.1074/mcp.M500279-MCP200

K. Sommer, S. Peters, I. Robins, M. Raap, G. Wiedemann et al., A preclinical model for experimental chemotherapy of human head and neck cancer, International Journal of Oncology, vol.18, pp.1145-1154, 2001.
DOI : 10.3892/ijo.18.6.1145

H. Wang, Y. Shi, L. Li, J. Guo, Y. Zhang et al., Treatment with resveratrol attenuates sublesional bone loss in spinal cord-injured rats, British Journal of Pharmacology, vol.315, issue.Suppl. 1, pp.796-806, 2013.
DOI : 10.1016/j.yexcr.2009.07.030

URL : http://onlinelibrary.wiley.com/doi/10.1111/bph.12301/pdf

S. Dhar, N. Kolishetti, S. Lippard, and O. Farokhzad, Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo, Proceedings of the National Academy of Sciences, vol.108, issue.5, pp.1850-1855, 2011.
DOI : 10.1517/17425247.5.3.309

F. Dieudonné, A. Marion, P. Marie, and D. Modrowski, Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice, Journal of Bone and Mineral Research, vol.14, issue.10, pp.2118-2129, 2012.
DOI : 10.1158/1078-0432.CCR-07-2223

L. Hanly, R. Figueredo, M. Rieder, J. Koropatnick, and G. Koren, The effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model, Anticancer Res, vol.32, pp.3791-3798, 2012.

P. Ottewell, H. Mönkkönen, M. Jones, D. Lefley, R. Coleman et al., Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.16, pp.1167-1178, 2008.
DOI : 10.1093/jnci/djn240

S. Bielack, D. Carrle, P. Casali, . Esmo-guidelines-working, and . Group, Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann Oncol, vol.20, issue.4, pp.137-139, 2009.
DOI : 10.1093/annonc/mdn102

URL : https://academic.oup.com/annonc/article-pdf/19/suppl_2/ii94/726991/mdn102.pdf

L. Brugières and S. Piperno-neumann, Chemotherapy for osteosarcoma, Oncologie, vol.2, issue.Suppl2, pp.164-169, 2007.
DOI : 10.1056/NEJM198606193142502

W. Yang, J. Soares, P. Greninger, E. Edelman, H. Lightfoot et al., Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Research, vol.41, issue.D1, pp.955-961, 2013.
DOI : 10.1093/nar/gks1111

S. Georges, J. Chesneau, S. Hervouet, J. Taurelle, F. Gouin et al., A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis, European Journal of Cancer, vol.49, issue.9, pp.2253-2263, 2013.
DOI : 10.1016/j.ejca.2013.02.020

H. Cole, J. Ichikawa, D. Colvin, O. Rear, L. Schoenecker et al., Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis, Journal of Orthopaedic Research, vol.48, issue.12, pp.1957-1962, 2011.
DOI : 10.1016/j.bone.2010.05.033

Ö. Uluçkan, A. Segaliny, S. Botter, J. Santiago, and A. Mutsaers, Preclinical mouse models of osteosarcoma, BoneKEy Reports, vol.4, p.670, 2015.
DOI : 10.1038/bonekey.2015.37

S. Eikenberry, A tumor cord model for Doxorubicin delivery and dose optimization in solid tumors, Theoretical Biology and Medical Modelling, vol.6, issue.1, p.16, 2009.
DOI : 10.1186/1742-4682-6-16

J. Lankelma, H. Dekker, F. Luque, S. Luykx, K. Hoekman et al., Doxorubicin gradients in human breast cancer, Clin Cancer Res, vol.5, pp.1703-1707, 1999.

A. Primeau, A. Rendon, D. Hedley, L. Lilge, and I. Tannock, The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors, Clinical Cancer Research, vol.11, issue.24, pp.8782-8788, 2005.
DOI : 10.1158/1078-0432.CCR-05-1664

J. Brown and W. Wilson, Exploiting tumour hypoxia in cancer treatment, Nature Reviews Cancer, vol.56, issue.6, pp.437-447, 2004.
DOI : 10.1016/0360-3016(96)00132-0

A. Minchinton and I. Tannock, Drug penetration in solid tumours, Nature Reviews Cancer, vol.23, issue.1, pp.583-592, 2006.
DOI : 10.1177/002215549704500909

R. Sullivan, G. Paré, L. Frederiksen, G. Semenza, and C. Graham, Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity, Molecular Cancer Therapeutics, vol.7, issue.7, pp.1961-1973, 2008.
DOI : 10.1158/1535-7163.MCT-08-0198

URL : http://mct.aacrjournals.org/content/molcanther/7/7/1961.full.pdf

N. Faye, Thérapie cellulaire de l'angiogenèse tumorale: évaluation par imagerie morphologique et fonctionnelle en IRM et vidéomicroscopie de fluorescence, 2011.

A. Jha, K. Tharp, J. Ye, J. Santiago-ortiz, W. Jackson et al., Enhanced survival and engraftment of transplanted stem cells using growth factor sequestering hydrogels, Biomaterials, vol.47, pp.1-12, 2015.
DOI : 10.1016/j.biomaterials.2014.12.043

J. Au, S. Jang, and M. Wientjes, Clinical aspects of drug delivery to tumors, Journal of Controlled Release, vol.78, issue.1-3, pp.81-95, 2002.
DOI : 10.1016/S0168-3659(01)00488-6

R. Erapaneedi, V. Belousov, M. Schäfers, and F. Kiefer, A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level, The EMBO Journal, vol.35, issue.1, pp.102-113, 2016.
DOI : 10.15252/embj.201592775